Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines.
Methotrexate (MTX) is widely used as disease modifying treatment for psoriasis and psoriatic arthritis (PsA). Rheumatological and dermatological guidelines to prevent MTX-induced adverse events diverge in the number and frequency of blood tests. These differences are not based on evidence indicating...
Main Authors: | Felien T M Busger Op Vollenbroek, Carine J M Doggen, René W A Janssens, Hein J Bernelot Moens |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5865732?pdf=render |
Similar Items
-
«METHOTREXATE ERA» IN CHILDREN RHEUMATOLOGY
by: S.R. Rodionovskaya, et al.
Published: (2006-03-01) -
«METHOTREXATE ERA» IN CHILDREN RHEUMATOLOGY
by: S.R. Rodionovskaya, et al.
Published: (2006-01-01) -
Methotrexate: ‘Lessons from Rheumatology’
by: Remo Panaccione
Published: (2005-01-01) -
Methotrexate Management in Psoriasis: Are We Following the Guidelines?
by: Tora Lindqvist, et al.
Published: (2018-01-01) -
The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis – 2019
by: Gustavo Gomes Resende, et al.
Published: (2020-02-01)